[Hypercalcemia: a finding indicative of a prostatic adenocarcinoma].
Calcemic alterations in prostate cancer are extremely rare. Hypercalcemia may be seen in cases of multiple osseous dissemination, and even in the absence of this in response to humoral mechanisms. The existence of hypercalcemia may indicate tumoural recurrence, and may at times be a datum prior to the diagnosis of the tumour. In cases of disseminated prostate adenocarcinoma hormones treatment may secure the normalization of blood calcium. We present a case of prostate carcinoma diagnosed in a 76-year-old patient, as a result of the presentation of a hypercalcemic metabolic syndrome, which was corrected after treatment by means of complete androgenic blocking.
Llarena Ibarguren
R
R
Acha Pérez
M
M
Zabala Egurrola
J A
JA
Pertusa Peña
C
C
D000230:Adenocarcinoma / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D003534:Cyproterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004232:Diuretics / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology*; D016729:Leuprolide; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood* / Q000150:complications / Q000188:drug therapy
D000726:Androgen Antagonists; D004232:Diuretics; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate; D003534:Cyproterone; D016729:Leuprolide
Hipercalcemia: dato revelador de un adenocarcinoma prostático.